S. Locarnini

P. Angus, A. Sheil, S. Locarnini, 1999, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Management of treatment failure in chronic hepatitis B.

F. Zoulim, S. Locarnini, 2012, Journal of hepatology.

Detection of hepatitis A virus in the feces of patients with naturally acquired infections.

S. Locarnini, I. Gust, A. Coulepis, 1980, The Journal of infectious diseases.

Molecular Virology and Life Cycle

S. Locarnini, Darren Wong, 2018 .

Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine Therapy

Bin Zhou, Yungang He, Guo-Ping Zhao, 2015, Scientific Reports.

Clinical significance of hepatitis B virion and SVP productivity: relationships between intrahepatic and serum markers in chronic hepatitis B patients

L. Lesmana, R. Hammond, S. Lim, 2014, United European gastroenterology journal.

Role of Resistance Testing During Oral Antiviral Therapy of Chronic Hepatitis B

S. Locarnini, U. Devi, 2012, Current Hepatitis Reports.

Antiviral Drug Resistance Testing in Patients with Chronic Hepatitis B

V. Wong, H. Chan, S. Locarnini, 2011, Digestive Diseases and Sciences.

How infectious is the hepatitis B virus? Readings from the occult

G. Raimondo, S. Locarnini, 2018, Gut.

Lamivudine resistant occult HBV: implications for public health?

S. Locarnini, S. Bowden, A. Bartholomeusz, 2003, Journal of hepatology.

The virological aspects of hepatitis B.

S. Locarnini, Z. Valaydon, 2017, Best practice & research. Clinical gastroenterology.

Hepatitis B virus splicing is enhanced prior to development of hepatocellular carcinoma.

P. Angus, P. Revill, S. Locarnini, 2013, Journal of hepatology.

Mutations in the hepatitis B virus precore/core gene and core promoter in patients with severe recurrent disease following liver transplantation

P. Angus, S. Locarnini, G. McCaughan, 1996, Hepatology.

HBV genotyping and analysis for unique mutations.

S. Locarnini, A. Ayres, A. Bartholomeusz, 2004, Methods in molecular medicine.

The hepatitis B virus and common mutants.

S. Locarnini, A. Bartholomeusz, J. McMillan, 2003, Seminars in liver disease.

Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus.

S. Lewin, K. Ruxrungtham, C. Thio, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cross-Resistance Testing of Antihepadnaviral Compounds Using Novel Recombinant Baculoviruses Which Encode Drug-Resistant Strains of Hepatitis B Virus

M. Manns, C. Trautwein, H. Isom, 2001, Antimicrobial Agents and Chemotherapy.

Hepatitis: Monitoring drug therapy for hepatitis B—a global challenge?

S. Locarnini, Tin Nguyen, 2009, Nature Reviews Gastroenterology &Hepatology.

Epidemiological and virological characteristics of 2 subgroups of hepatitis B virus genotype C.

Kwong-Sak Leung, Kin-Hong Lee, Angeline Bartholomeusz, 2005, The Journal of infectious diseases.

Hepatitis B virus precore mutant infection is associated with severe recurrent disease after liver transplantation

P. Angus, S. Locarnini, G. McCaughan, 1995, Hepatology.

Potential threat of drug-resistant and vaccine-escape HBV mutants to public health.

S. Locarnini, C. Teo, 2010, Antiviral therapy.

Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update

M. Kumar, Chien-Jen Chen, Ding‐Shinn Chen, 2015, Hepatology International.

Spread of bloodborne viruses among Australian prison entrants

S. Locarnini, N. Crofts, X. Ping, 1995, BMJ.

Hepatitis C virus infection among a cohort of Victorian injecting drug users

Nick Crofts, S. Locarnini, J. Hopper, 1993, The Medical journal of Australia.

Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent.

M. Yuen, Ching-lung Lai, D. Lewis, 2015, Antiviral research.

Hepatitis B virus resistance to nucleos(t)ide analogues.

F. Zoulim, S. Locarnini, 2009, Gastroenterology.

The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging.

S. Locarnini, J. Feld, D. Colledge, 2007, Antiviral research.

Nomenclature for antiviral‐resistant human hepatitis B virus mutations in the polymerase region

D. Richman, L. Stuyver, R. Schinazi, 2001, Hepatology.

Genotyping and genomic sequencing in clinical practice.

R. Gish, S. Locarnini, 2007, Clinics in liver disease.

Studying the treatment of chronic hepatitis B viral infection in special populations.

R. Gish, S. Locarnini, 2004, Methods in molecular medicine.

Resistance of Hepatitis B Virus to Antiviral Drugs: Current Aspects and Directions for Future Investigation

W. Delaney, S. Locarnini, W E Delaney, 2001, Antiviral chemistry & chemotherapy.

Antiviral chemotherapy for the treatment of hepatitis B virus infections.

S. Locarnini, J. Torresi, S. Locarnini, 2000, Gastroenterology.

Drug-Resistant Strains of Hepatitis B Virus Recombinant Baculoviruses Which Encode Antihepadnaviral Compounds Using Novel Cross-Resistance Testing of

M. Manns, C. Trautwein, H. Isom, 2000 .

Preclinical aspects of lamivudine and famciclovir against hepatitis B virus

S. Locarnini, T. Shaw, S. Locarnini, 1999, Journal of viral hepatitis.

Antiviral strategies in chronic hepatitis B virus infection: I. Establishment of an in vitro system using the duck hepatitis B virus model

S. Locarnini, I. Gust, C. Birch, 1990, Journal of medical virology.

Interaction between ganciclovir and foscarnet as inhibitors of duck hepatitis B virus replication in vitro

S. Locarnini, G. Civitico, T. Shaw, 1996, Antimicrobial agents and chemotherapy.

Coproantibodies in hepatitis A: detection by enzyme-linked immunosorbent assay and immune electron microscopy

S. Locarnini, I. Gust, A. Coulepis, 1980, Journal of clinical microbiology.

Autoantibody to intermediate filaments in viral hepatitis.

S. Locarnini, I. Gust, B. Toh, 1981, Clinical immunology and immunopathology.

When Two Infections Are Better Than One: The Exceptional Role of GB Virus-C (GBV-C) in HIV Disease

D. Dieterich, H. Tillmann, S. Locarnini, 2003 .

Hepatitis B virus infection

Ding‐Shinn Chen, M. Yuen, H. Janssen, 2018, Nature Reviews Disease Primers.

The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes

S. Locarnini, S. Bowden, S. Locarnini, 1995, Journal of virology.

The role of quantitative hepatitis B surface antigen revisited.

Vincent Wai-Sun Wong, V. Wong, H. Chan, 2017, Journal of hepatology.

Molecular virology of hepatitis B virus and the development of antiviral drug resistance

M. Omata, S. Locarnini, 2006 .

HBV core sequence: definition of genotype‐specific variability and correlation with geographical origin

R. Gish, A. Basuni, W. Carman, 2004, Journal of viral hepatitis.

Genetic Diversity of Hepatitis B Virus Strains Derived Worldwide: Genotypes, Subgenotypes, and HBsAg Subtypes

P. Coursaget, I. Mushahwar, S. Locarnini, 2004, Intervirology.

The evolution and clinical impact of hepatitis B virus genome diversity

H. Netter, P. Revill, S. Locarnini, 2020, Nature Reviews Gastroenterology & Hepatology.

Stop codons in the hepatitis B surface proteins are enriched during antiviral therapy and are associated with host cell apoptosis.

N. Warner, S. Locarnini, S. Soppe, 2017, Virology.

Anti-viral medication to prevent hcc development: where are we now?

N. Warner, S. Locarnini, Tin Nguyen, 2009 .

Article Commentary: Can Antiviral Therapy for Chronic Hepatitis B Enhance the Progression to Hepatocellular Carcinoma?

N. Warner, S. Locarnini, 2009, Antiviral therapy.

[486] UNDERSTANDING HBV RESISTANCE TO TELBIVUDINE: MOLECULAR MODELLING AND DATABASE MINING

S. Locarnini, M. Kuiper, L. Yuen, 2007 .

Resistance surveillance of HBEAG— chronic hepatitis B (CHB) patients treated for two years with adefovir dipivoxil (ADV)

M. Wulfsohn, C. Gibbs, P. Angus, 2003 .

Hepatitis B viral resistance: mechanisms and diagnosis.

S. Locarnini, 2003, Journal of hepatology.

Monitoring Drug Resistance in Chronic Hepatitis B Virus (HBV)-Infected Patients during Lamivudine Therapy: Evaluation of Performance of INNO-LiPA HBV DR Assay

Fabien Zoulim, Anna S. F. Lok, A. Lok, 2002, Journal of Clinical Microbiology.

Analysis of hepatitis B viral load decline under potent therapy: Complex decay profiles observed

Alan S. Perelson, Scott Bowden, Ruy M. Ribeiro, 2001, Hepatology.

Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro

S. Locarnini, D. Colledge, T. Shaw, 1997, Hepatology.

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.

Angeline Bartholomeusz, C. Gibbs, P. Angus, 2003, Gastroenterology.

Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV.

C. Gibbs, S. Locarnini, M. Bonacini, 2002, Gastroenterology.

In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil.

M. Manns, C. Trautwein, H. Isom, 2001, Antimicrobial agents and chemotherapy.

In Vitro Antihepadnaviral Activities of Combinations of Penciclovir, Lamivudine, and Adefovir

S. Locarnini, G. Civitico, D. Colledge, 2000, Antimicrobial Agents and Chemotherapy.

Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients.

S. Locarnini, C. Birch, 1999, Journal of hepatology.

Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation.

P. Angus, T. Aye, S. Locarnini, 1997, Journal of hepatology.

The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo

S. Locarnini, T. Shaw, E. Lin, 1996, Antimicrobial agents and chemotherapy.

Treatment of HIV/HBV coinfection: clinical and virologic issues.

C. Thio, S. Locarnini, 2007, AIDS reviews.

Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy

S. Lewin, D. Cooper, C. Thio, 2006, AIDS.

Selection of Hepatitis B Virus Polymerase Mutations in HIV-Coinfected Patients Treated with Tenofovir

F. Tacke, B. Rodés, V. Soriano, 2005, Antiviral therapy.

Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure.

G. Lau, S. Locarnini, A. Ayres, 2003, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

New insight in the pathobiology of hepatitis B virus infection

M. Dandri, S. Locarnini, Maura Dandri, 2012, Gut.

Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: Hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern

H. Tillmann, S. Locarnini, J. Wiegand, 2010, Journal of medical virology.

Mutations in the hepatitis B virus DNA polymerase associated with antiviral resistance

D. Pillay, P. Cane, S. Locarnini, 1998 .

Hepatitis B virus: pathogenesis, viral intermediates, and viral replication.

S. Locarnini, Jia-Ye Lee, 2004, Clinics in liver disease.

Molecular virology and the development of resistant mutants: implications for therapy.

S. Locarnini, 2005, Seminars in liver disease.

Combination Chemotherapy for Hepatitis B Virus

S. Locarnini, T. Shaw, 2000, Drugs.

In Vitro Study of the Effects of Precore and Lamivudine-Resistant Mutations on Hepatitis B Virus Replication

H. Isom, W. Delaney, S. Locarnini, 2007, Journal of Virology.

Chronic hepatitis B: current testing strategies.

R. Gish, S. Locarnini, 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine‐resistant HBV in vitro

H. Isom, W. Delaney, S. Locarnini, 2003, Hepatology.

Evolving therapies for the treatment of chronic hepatitis B virus infection

S. Locarnini, A. Bartholomeusz, W. Iv, 2002, Expert opinion on investigational drugs.

Hepatitis B virus surface antigen and polymerase gene variants: Potential virological and clinical significance

S. Locarnini, 1998, Hepatology.

Hepatitis B Virus

S. Locarnini, S. Bell, A. Thompson, 2009 .

Antiviral drug‐resistant HBV: Standardization of nomenclature and assays and recommendations for management

Angeline Bartholomeusz, Carla Kuiken, Fabien Zoulim, 2007, Hepatology.

HIV, HBV, HCV, and STIs: similarities and differences

S. Locarnini, M. Kidd, M. Danta, 2008 .

Hepatic failure due to fibrosing cholestatic hepatitis in a patient with pre-surface mutant hepatitis B virus and mixed connective tissue disease treated with prednisolone and chloroquine.

P. Angus, S. Locarnini, S. Roberts, 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Novel approaches in the management of chronic HBV infection

S. Locarnini, P. Furman, A. Bartholomeusz, 2003 .

Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies.

S. Lewin, S. Locarnini, T. Walters, 2002, Antiviral research.

Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitis.

S. Locarnini, T. Shaw, 2008, Liver.

Lamivudine-Resistant Hepatitis B Virus and Ongoing Lamivudine Therapy: Stop the Merry-Go-Round, It'S Time to get off!

P. Angus, S. Locarnini, 2004, Antiviral therapy.

Erratum to: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

Y. Liaw, J. Kao, Chun-Jen Liu, 2012, Hepatology International.

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

Jia-Horng Kao, Jin-Lin Hou, Masao Omata, 2012, Hepatology International.

Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance

S. Lewin, K. Ruxrungtham, P. Angus, 2008, Hepatology.

Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach.

Jean-Michel Pawlotsky, Geoffrey Dusheiko, Fabien Zoulim, 2008, Gastroenterology.

The L80I Substitution in the Reverse Transcriptase Domain of the Hepatitis B Virus Polymerase Is Associated with Lamivudine Resistance and Enhanced Viral Replication In Vitro

N. Warner, S. Locarnini, M. Kuiper, 2007, Antimicrobial Agents and Chemotherapy.

Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro

P. Angus, S. Locarnini, T. Shaw, 1995, Hepatology.

In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus

S. Locarnini, G. Civitico, M. Boyd, 1994, Antimicrobial Agents and Chemotherapy.

Treatment of chronic hepatitis B: current challenges and future directions

S. Locarnini, R. Chin, 2003, Reviews in medical virology.

Duck Hepatitis B Virus Replication in Primary Bile Duct Epithelial Cells

P. Angus, J. Culvenor, S. Locarnini, 2001, Journal of Virology.

Animal Models for Hepatitis B Infections — Duck Hepatitis

S. Locarnini, T. Shaw, C. Luscombe, 1999 .

and Tim and Adefovir Combinations of Penciclovir , Lamivudine , In Vitro Antihepadnaviral Activities of

S. Locarnini, G. Civitico, D. Colledge, 1999 .

Inhibition of Duck Hepatitis B Virus Replication by 9-(2-Phosphonylmethoxyethyl)adenine, an Acyclic Phosphonate Nucleoside Analogue

P. Angus, S. Locarnini, R. Smallwood, 1998, Antimicrobial Agents and Chemotherapy.

Reversion of duck hepatitis B virus DNA replication in vivo following cessation of treatment with the nucleoside analogue ganciclovir.

S. Locarnini, S. Bowden, J. Dean, 1995, Antiviral research.

Inhibition of duck hepatitis B virus DNA replication by antiviral chemotherapy with ganciclovir-nalidixic acid

S. Locarnini, S. Bowden, T. Shaw, 1995, Antimicrobial agents and chemotherapy.

Alterations in intrahepatic expression of duck hepatitis B viral markers with ganciclovir chemotherapy.

S. Locarnini, S. Bowden, J. Pedersen, 2008, Liver.

The use of ampligen alone and in combination with ganciclovir and coumermycin A1 for the treatment of ducks congenitally-infected with duck hepatitis B virus.

S. Locarnini, S. Bowden, J. Niu, 1993, Antiviral research.

Treatment of Chronic Viral Hepatitis B and Drug Resistant Variants

S. Locarnini, P. Desmond, Tin Nguyen, 2012 .

Retransplantation for precore mutant-related chronic hepatitis B infection: prolonged survival in a patient receiving sequential ganciclovir/famciclovir therapy.

P. Angus, S. Locarnini, G. McCaughan, 1996, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Update on HIV/HBV Coinfection: Pathogenesis and Treatment

S. Locarnini, M. Peters, J. Sasadeusz, 2002 .

Cellular and virological mechanisms of HBV drug resistance.

S. Locarnini, W. Mason, Stephen Locarnini, 2006, Journal of hepatology.

Chemotherapy for hepatitis B: new treatment options necessitate reappraisal of traditional endpoints.

S. Locarnini, S. Bowden, T. Shaw, 2002, Gastroenterology.

96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B.

K. Yuen, J. Luk, S. Locarnini, 2008, Journal of hepatology.

A Randomized, Placebo-Controlled Trial of Thymosin-α1 and Lymphoblastoid Interferon for Hbeag-Positive Chronic Hepatitis B

D. Machin, E. Koay, C. Wai, 2005, Antiviral Therapy.

Chronic hepatitis B: treatment alert

Y. Liaw, S. Sarin, N. Leung, 2006 .

High frequency of lamivudine resistance mutations in Brazilian patients co‐infected with HIV and hepatitis B

R. Sitnik, S. Locarnini, M. Gomes-Gouvêa, 2010, Journal of medical virology.

Relevance of HBV mutations in severity and progression of chronic hepatitis B

S. Locarnini, 2004 .

Molecular virology of hepatitis B virus.

S. Locarnini, 2004, Seminars in liver disease.

Selection of Hepatitis B Virus (HBV) Vaccine Escape Mutants in HBV-Infected and HBV/HIV-Coinfected Patients Failing Antiretroviral Drugs With Anti-HBV Activity

V. Soriano, F. Zoulim, S. Locarnini, 2007, Journal of acquired immune deficiency syndromes.

SeqHepB: a sequence analysis program and relational database system for chronic hepatitis B.

S. Locarnini, D. Colledge, L. Yuen, 2007, Antiviral research.

Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report.

P. Marcellin, J. Kao, H. Chan, 2011, Journal of hepatology.

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

C. Gibbs, P. Marcellin, F. Zoulim, 2004, Gastroenterology.

1141 Complete genotypic and phenotypic analyses of HBV mutations identified in HBEAG-negative chronic hepatitis B patients receiving 96 weeks of adefovir dipivoxil (ADV)

M. Wulfsohn, C. Gibbs, P. Angus, 2003 .

HBV Therapy and the Problem of Drug Resistance

S. Locarnini, A. Thompson, 2014 .

Global control of hepatitis B virus: does treatment-induced antigenic change affect immunization?

R. Tedder, S. Locarnini, J. Torresi, 2010, Bulletin of the World Health Organization.

HBV drug resistance: mechanisms, detection and interpretation.

Angeline Bartholomeusz, Tim Shaw, S. Locarnini, 2006, Journal of hepatology.

Comparison of Sequence Analysis and a Novel Discriminatory Real-Time PCR Assay for Detection and Quantification of Lamivudine-Resistant Hepatitis B Virus Strains

S. Lewin, S. Locarnini, S. Bowden, 2004, Journal of Clinical Microbiology.

Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities.

D. Lewis, R. Gish, T. Schluep, 2015, Antiviral research.

Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus.

S. Locarnini, D. Samarasinghe, M. Levy, 2014, Journal of hepatology.

Perinatal transmission of hepatitis B virus: an Australian experience

S. Locarnini, M. Maley, M. Levy, 2009, The Medical journal of Australia.

Anti‐viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post‐partum flare

S. Locarnini, S. Strasser, D. Samarasinghe, 2014, Alimentary pharmacology & therapeutics.

RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg

S. Kanner, M. Yuen, D. Lewis, 2017, Science Translational Medicine.

Mechanisms of Hepatitis B Virus Resistance Development

N. Warner, S. Locarnini, 2014, Intervirology.

Drug resistance in antiviral therapy.

Scott Bowden, S. Locarnini, S. Bowden, 2010, Clinics in liver disease.

Review HBV drug resistance: Mechanisms, detection and interpretation

S. Locarnini, T. Shaw, A. Bartholomeusz, 2006 .

Combination of HBIG and Lamivudine- Resistant Mutations: A Formula for Trouble?

C. Trautwein, J. Klempnauer, S. Locarnini, 2002 .

HBV mutations in untreated HIV-HBV co-infection using genomic length sequencing.

S. Lewin, K. Ruxrungtham, C. Thio, 2010, Virology.

Transmission of antiviral drug resistant hepatitis B virus: Implications for public health and patient management

S. Locarnini, 2010, Journal of gastroenterology and hepatology.

Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure

S. Locarnini, 2008, Hepatology international.

A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B.

D. Machin, E. Koay, A. Wee, 2006, Antiviral therapy.

In Vitro Studies Show that Sequence Variability Contributes to Marked Variation in Hepatitis B Virus Replication, Protein Expression, and Function Observed across Genotypes

P. Revill, N. Warner, S. Locarnini, 2016, Journal of Virology.

Targeting the hepatitis B virus precore antigen with a novel IgNAR single variable domain intrabody.

O. Dolezal, P. Revill, S. Locarnini, 2011, Virology.

Cellular response to conditional expression of the hepatitis B virus precore and core proteins in cultured hepatoma (Huh-7) cells.

S. Lemon, S. Locarnini, M. Beard, 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Hepatitis B virus mutants and fulminant hepatitis B: Fitness plus phenotype

S. Locarnini, A. Bartholomeusz, 2001, Hepatology.

N. Warner, S. Locarnini, E. Vincan, 2012 .

Chapter 6 – Replication of Hepatitis B Virus

N. Warner, S. Locarnini, 2012 .

Viral Adaptation to Host Immune Responses Occurs in Chronic Hepatitis B Virus (HBV) Infection, and Adaptation Is Greatest in HBV e Antigen-Negative Disease

I. James, S. Mallal, S. Lewin, 2011, Journal of Virology.

The phenotype of hepatitis B virus–specific T cells differ in the liver and blood in chronic hepatitis B virus infection

S. Lewin, S. Kent, S. Locarnini, 2007, Hepatology.

Chapter 7 – Replication of Hepatitis B Virus and Pathogenesis of Disease

S. Lewin, S. Locarnini, Judy J. Chang, 2006 .

Seroepidemiology of hepatitis E in selected Australian populations

S. Locarnini, N. Crofts, L. Moaven, 1995, Journal of medical virology.

INHIBITION OF HBV DNA REPLICATION BY GANCICLOVIR IN PATIENTS WITH AIDS

S. Locarnini, I. Gust, Ron Lucas, 1989, The Lancet.

Effect of Phyllanthus amarus on duck hepatitis B virus replication in vivo

S. Locarnini, I. Gust, M. Qiao, 1990, Journal of medical virology.

Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy.

V. Wong, J. Sung, S. Locarnini, 2005, Gastroenterology.

Chronic hepatitis B: recommendations for therapy based on the natural history of disease in Australian patients.

A. Thompson, S. Locarnini, S. Bell, 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Structural organization of the hepatitis B virus minichromosome.

M. Manns, C. Trautwein, H. Zentgraf, 2001, Journal of molecular biology.

A parsimonious method for screening drug combinations for antihepadnaviral activity using a parametric dose-response surface approach.

S. Locarnini, T. Shaw, 2004, Methods in molecular medicine.

The new front‐line in hepatitis B/D research: Identification and blocking of a functional receptor

N. Warner, S. Locarnini, 2013, Hepatology.

Serum hepatitis B surface antigen and hepatitis B e antigen titers: Disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers

S. Lewin, S. Locarnini, E. Gane, 2010, Hepatology.

Clinical significance of precore and core promoter mutations in genotype D hepatitis B‐related chronic liver disease

R. Malekzadeh, H. Poustchi, A. Mohamadkhani, 2008, Journal of viral hepatitis.

Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B

M. Buti, P. Marcellin, R. Hammond, 2016, Gut.

Comparison of Real-Time PCR Assays for Monitoring Serum Hepatitis B Virus DNA Levels during Antiviral Therapy

J. Luk, S. Lewin, S. Locarnini, 2006, Journal of Clinical Microbiology.

Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia.

S. Locarnini, S. Bell, P. Desmond, 2010, Journal of hepatology.

The natural history and the staging of chronic hepatitis B: time for reevaluation of the virus-host relationship based on molecular virology and immunopathogenesis considerations?

S. Locarnini, K. Visvanathan, A. Thompson, 2007, Gastroenterology.

Possible origins and evolution of the hepatitis B virus (HBV).

S. Locarnini, L. Yuen, M. Littlejohn, 2013, Seminars in cancer biology.

Antiviral resistance and direct-acting antiviral agents for HCV.

S. Locarnini, A. Aloia, M. Beard, 2012, Antiviral therapy.

Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B

P. Angus, J. George, S. Locarnini, 2010, Gut.

Prevalence of HBsAg mutants and impact of hepatitis B infant immunisation in four Pacific Island countries.

A. Basuni, W. Carman, S. Locarnini, 2004, Vaccine.

Molecular Diagnostics in Hepatitis B

S. Locarnini, S. Bowden, 2006 .

Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA.

M. Manns, C. Trautwein, S. Kubicka, 2003, Gastroenterology.

Combination chemotherapy for hepatitis B virus: the path forward?

S. Locarnini, T. Shaw, 2000, Drugs.

Abnormal Laboratory Results: Hepatitis B: issues in laboratory diagnosis and vaccination

S. Locarnini, D. Siebert, 1998 .

Clinical and virological factors that predict post partum flares in pregnant women with chronic HBV

S. Lewin, S. Locarnini, J. Sasadeusz, 2013 .

Origins and Evolution of Hepatitis B Virus and Hepatitis D Virus.

S. Locarnini, L. Yuen, M. Littlejohn, 2016, Cold Spring Harbor perspectives in medicine.

Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro

Domenico Di Carlo, F. Ceccherini‐Silberstein, H. Fleury, 2017, Oncotarget.

Diagnostic Problems Caused by HBsAg Mutants – A Consensus Report of an Expert Meeting

P. Coursaget, Yoshiyuki Suzuki, O. Yokosuka, 2004, Intervirology.

Hepatitis B virus genotypes, core gene variability and ethnicity in the Pacific region.

A. Basuni, W. Carman, S. Locarnini, 2004, Journal of hepatology.

Origins and Evolution of the Primate Hepatitis B Virus

S. Locarnini, L. Yuen, M. Littlejohn, 2021, Frontiers in Microbiology.

Sub-optimal protection against past hepatitis B virus infection where subtype mismatch exists between vaccine and circulating viral genotype in northern Australia.

S. Tong, S. Locarnini, N. Wood, 2018, Vaccine.

Real‐world application of the Xpert® HBV viral load assay on serum and dried blood spots

S. Locarnini, K. Jackson, R. Tekoaua, 2020, Journal of medical virology.

Serum guanase activity in hepatitis C virus infection.

S. Locarnini, J. Li, G. Cooksley, 1994, Advances in experimental medicine and biology.

Changing landscape of antiviral resistance management in chronic hepatitis B

S. Locarnini, P. Desmond, Tin Nguyen, 2008, Journal of gastroenterology and hepatology.

Clinical relevance of viral dynamics and genotypes in hepatitis B virus

S. Locarnini, 2002, Journal of gastroenterology and hepatology.

Phylogenetic analysis of hepatitis B virus genotype F complete genome sequences from Chilean patients with chronic infection

J. R. Rebello Pinho, F. Carrilho, S. Locarnini, 2011, Journal of medical virology.

Molecular and clinical characteristics of hepatitis B virus in Korea

P. Revill, S. Locarnini, J. Heo, 2010, Journal of medical virology.

Blood-borne virus infections among Australian injecting drug users: Implications for spread of HIV

S. Locarnini, J. Hopper, N. Crofts, 1994, European Journal of Epidemiology.

[505] MULTIDRUG RESISTANCE AND CROSS-RESISTANCE PATHWAYS IN HBV AS A CONSEQUENCE OF TREATMENT FAILURE

S. Locarnini, L. Yuen, M. Littlejohn, 2007 .

Assays for Hepatitis B Virus DNA-and RNA-Dependent DNA Polymerase Activities.

S. Locarnini, T. Shaw, 2000, Methods in molecular medicine.

Molecular virology of hepatitis B virus, sub‐genotype C4 in northern Australian Indigenous populations

B. Cowie, S. Tong, S. Locarnini, 2014, Journal of medical virology.

Chronic hepatitis B: the therapeutic challenge.

S. Locarnini, J. Newbold, 1997, The Journal of antimicrobial chemotherapy.

Analysis of Hepatitis B Virus Haplotype Diversity Detects Striking Sequence Conservation Across Genotypes and Chronic Disease Phase

P. Marcellin, H. Janssen, A. Gaggar, 2020, Hepatology.

Analysis of the in vitro replication phenotype of African hepatitis B virus (HBV) genotypes and subgenotypes present in Australia identifies marked differences in DNA and protein expression.

P. Revill, S. Locarnini, W. Hardikar, 2019, Virology.

Molecular characterization of hepatitis B virus (HBV) in African children living in Australia identifies genotypes and variants associated with poor clinical outcome.

P. Revill, S. Locarnini, W. Hardikar, 2018, The Journal of general virology.

World Gastroenterology Organisation Global Guideline Hepatitis B: September 2015.

M. Yuen, Z. Abbas, S. Lim, 2016, Journal of clinical gastroenterology.

[415] THE ACTIVE METABOLITE OF LB80380/ANA380, A NOVEL NUCLEOTIDE ANALOG, EXHIBITS ACTIVITY IN VITRO AGAINST MULTIPLE CLINICALLY RELEVANT HEPATITIS B VIRUS MUTANTS

K. Steffy, S. Locarnini, T. Shaw, 2007 .

Increased prevalence of HBV envelope mutants in Taiwan: an emerging public health risk or a false alarm?

S. Locarnini, D. Shouval, 2012, Gastroenterology.

Hepatitis B and D in the Pacific Islands of Kiribati.

S. Locarnini, S. Nicholson, K. Jackson, 2020, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs.

A. Lok, Ding‐Shinn Chen, A. Hatzakis, 2015, Journal of hepatology.

The relationship between a 27-nm virus-like particle and hepatitis A as demonstrated by immune electron microscopy.

S. Locarnini, I. Gust, A. Ferris, 1974, Intervirology.

Amino‐terminal epitopes are exposed when full‐length open reading frame 2 of hepatitis E virus is expressed in Escherichia coli, but carboxy‐terminal epitopes are masked

S. Locarnini, J. Torresi, Wan-fu Zhu, 1997, Journal of medical virology.

Diagnostics of Hepatitis B Virus: Standard of Care and Investigational

R. Gish, S. Locarnini, K. Jackson, 2018, Clinical liver disease.

Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg‐negative but not HBeAg‐positive chronic hepatitis B

S. Locarnini, S. Bell, P. Desmond, 2010, Liver international : official journal of the International Association for the Study of the Liver.

Therapies for hepatitis B: where to from here?

S. Locarnini, 2005, Gastroenterology.

Commonly Found Variations/Mutations in the HBsAg of Hepatitis B Virus in the Context of Effective Immunization Programs: Questionable Clinical and Public Health Significance

S. Locarnini, D. Shouval, 2014, Journal of Virology.

Resistance to anti-HCV protease inhibitors.

S. Locarnini, A. Thompson, M. Beard, 2011, Current opinion in virology.

Taxonomic classification of hepatitis A virus.

S. Locarnini, I. Gust, A. Coulepis, 1983, Intervirology.

Hepatitis G virus and fulminant hepatic failure: evidence for transfusion-related infection.

P. Angus, S. Locarnini, J. Kim, 1997, Journal of hepatology.

Five‐year efficacy and safety of tenofovir‐based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy

P. Angus, J. George, S. Locarnini, 2017, Liver international : official journal of the International Association for the Study of the Liver.

Tenofovir Rescue Therapy Achieves Long-Term Suppression of HBV Replication in Patients with Multi-Drug Resistant HBV: 4 Year Follow-Up of the TDF109 Cohort

P. Angus, J. George, S. Locarnini, 2012 .

PS-080-Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg < 100 IU/ml threshold

M. Yuen, D. Wong, R. Gish, 2019, Journal of Hepatology.

Locally acquired hepatitis E in the Northern Territory of Australia

D. Fisher, S. Locarnini, B. Currie, 1995, The Medical journal of Australia.

Monoclonal antibodies against hepatitis A virus

S. Locarnini, I. Gust, A. Coulepis, 1983, Journal of clinical microbiology.

Tracing Ancient Human Migrations into Sahul Using Hepatitis B Virus Genomes.

S. Tong, S. Locarnini, S. Duchêne, 2019, Molecular biology and evolution.

Parvovirus B19 In Hiv Infection: A treatable cause of anemia

S. Locarnini, D. Spelman, J. W. Spicer, 1996, Pathology.

Cellular topoisomerase I activity associated with HIV-1.

S. Locarnini, C. Birch, D. Jardine, 1993, AIDS research and human retroviruses.

Mechanisms of drug resistance and novel approaches to therapy for chronic hepatitis C

S. Locarnini, 2002, Journal of gastroenterology and hepatology.

A prospective study of acute viral hepatitis with particular reference to hepatitis A.

S. Locarnini, I. Gust, M. Wong, 1976, Bulletin of the World Health Organization.

Impact of Hepatitis B Virus Coinfection on Human T-Lymphotropic Virus Type 1 Clonality in an Indigenous Population of Central Australia

D. Purcell, G. Khoury, S. Locarnini, 2018, The Journal of infectious diseases.

Point of care and oral fluid hepatitis B testing in remote Indigenous communities of northern Australia

S. Tong, S. Locarnini, Joshua S. Davis, 2019, Journal of viral hepatitis.

Isolation of HIV‐1 from experimentally contaminated multidose local anaesthetic vials

S. Locarnini, J. Druce, C. Birch, 1995, The Medical journal of Australia.

Mother‐to‐baby transmission of hepatitis G virus

S. Locarnini, D. S. Bowden, L. Moaven, 1996, The Medical journal of Australia.

Prevalence of hepatitis G virus in Queensland blood donors

S. Locarnini, C. Hyland, D. S. Bowden, 1996, The Medical journal of Australia.

Generation of a Chimeric Hepatitis C Replicon Encoding a Genotype-6a NS3 Protease and Assessment of Boceprevir (SCH503034) Sensitivity and Drug-Associated Mutations

J. Howe, Zhuyan Guo, S. Locarnini, 2015, Antiviral therapy.

High level expression of the capsid protein of hepatitis E virus in diverse eukaryotic cells using the Semliki Forest virus replicon.

P. Lambert, S. Locarnini, J. Torresi, 1997, Journal of virological methods.

Toll‐like receptors, RIG‐I‐like RNA helicases and the antiviral innate immune response

S. Locarnini, Alex J V Thompson, Stephen A Locarnini, 2007, Immunology and cell biology.

Toll-like receptors , RIG-Ilike RNA helicases and the antiviral innate immune response

S. Locarnini, A. Thompson, 2007 .

Modulation of the immunogenicity of virus-like particles composed of mutant hepatitis B virus envelope subunits.

H. Netter, N. Warner, S. Locarnini, 2012, Antiviral research.

Serum immunoglobulin levels in acute A, B, and non-A, non-B hepatitis.

S. Locarnini, I. Gust, H. Zhuang, 1982, Gastroenterology.

Evidence that the genome of hepatitis A virus consists of single-stranded RNA

S. Locarnini, G. Tannock, I. Gust, 1981, Journal of virology.

The antibody response following hepatitis A infection.

S. Locarnini, I. Gust, A. Ferris, 1977, Intervirology.

The origin of the HM175 strain of hepatitis A virus.

S. Locarnini, I. Gust, S. Crowe, 1985, The Journal of infectious diseases.

Restricted replication of human hepatitis A virus in cell culture: intracellular biochemical studies

S. Locarnini, I. Gust, A. Coulepis, 1981, Journal of virology.

RNA Interference Therapy With ARC‐520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection

M. Manns, M. Yuen, R. Gish, 2020, Hepatology.

Sexual transmission of hepatitis B infection despite the presence of hepatitis B virus immunity in recipients of allogeneic bone marrow transplantation.

W. Au, Y. Kwong, S. Locarnini, 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Hepatocyte Produced Matrix Metalloproteinases Are Regulated by CD147 in Liver Fibrogenesis

S. Locarnini, S. Mclennan, G. McCaughan, 2014, PloS one.

The polypeptides of hepatitis A virus.

S. Locarnini, I. Gust, A. Coulepis, 1978, Intervirology.

Characterization of a precipitating antigen detected in the serum of patients with viral hepatitis

S. Locarnini, I. Gust, A. Coulepis, 1983, Journal of medical virology.

Iodination of hepatitis A virus reveals a fourth structural polypeptide

S. Locarnini, I. Gust, A. Coulepis, 1980, Journal of virology.

Should Aboriginals in the “Top End” of the Northern Territory be vaccinated against hepatitis A?

S. Locarnini, B. Currie, V. Krause, 1994, The Medical journal of Australia.

Biophysical and biochemical characterization of hepatitis A virus.

S. Locarnini, G. Tannock, I. Gust, 1982, Intervirology.

Molecular analysis of human immunodeficiency virus strains associated with a case of criminal transmission of the virus.

B. Hatch, P. Revill, S. Locarnini, 2000, The Journal of infectious diseases.

Detection of markers of hepatitis B infection in serum dried on to filter-paper: an application to field studies.

S. Locarnini, I. Gust, A. Coulepis, 1982, Bulletin of the World Health Organization.

736 LAMIVUDINE IN LATE PREGNANCY FOR PREVENTION OF HBV TRANSMISSION: EFFECTIVENESS AND DETECTION OF ANTIVIRAL RESISTANCE

S. Locarnini, M. Maley, M. Levy, 2011 .

New perspectives on the hepatitis B virus life cycle in the human liver.

P. Revill, S. Locarnini, 2016, The Journal of clinical investigation.

Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus‐1–hepatitis B virus coinfected individuals: Similar effectiveness of lamivudine, tenofovir, or combination therapy

A. Perelson, S. Lewin, K. Ruxrungtham, 2009, Hepatology.

Viral Hepatitis: Fourth Edition

A. Zuckerman, H. Thomas, A. Lok, 2013 .

SMALL INTERFERING RNAs

S. Locarnini, 2004 .

Predicting HBsAg clearance in genotype A chronic hepatitis B using HBsAg epitope profiling: A biomarker for functional cure

R. Hammond, K. Kitrinos, A. Gaggar, 2019, Liver international : official journal of the International Association for the Study of the Liver.

adefovir dipivoxil in chronic hepatitis B following failure of both lamivudine and Tenofovir disoproxil fumarate rescue therapy

P. Angus, J. George, S. Locarnini, 2022 .

The attachment receptor for hepatitis A virus.

S. Locarnini, 1997, Trends in microbiology.

Restrictive events in the replication of hepatitis A virus in vitro.

S. Locarnini, D. Anderson, I. Gust, 1985, Intervirology.

A phase 1 study to evaluate safety and tolerability of escalating single doses of the hepatitis B virus RNA interference drug ARC-521 in a healthy volunteer population

R. Gish, J. Lau, T. Schluep, 2017 .

Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen

M. Yuen, R. Gish, J. Lau, 2017 .

Treatment of Chronically HBV-Infected Chimpanzees with RNA Interference Therapeutic ARC-520 LED to Potent Reduction of Viral MRNA, DNA and Proteins without Observed Drug Resistance

S. Kanner, D. Lewis, R. Gish, 2016 .

Predicting HBsAg clearance responses during ARC-520 RNA interference (RNAi) therapy based on HBsAg epitope profile analysis

M. Yuen, R. Gish, R. Hammond, 2016 .

567 RELATIONSHIP BETWEEN HBV CCCDNA AND HBsAg LEVELS IS ASSOCIATED WITH HBeAg STATUSES OF CHRONIC HEPATITIS B PATIENTS

S. Locarnini, S. Bowden, G. Lau, 2009 .

A simple and inexpensive point-of-care test for hepatitis B surface antigen detection: serological and molecular evaluation

R. Gish, R. Hammond, S. Locarnini, 2014, Journal of viral hepatitis.

Persistent and transient antibody responses to hepatitis E virus detected by western immunoblot using open reading frame 2 and 3 and glutathione S-transferase fusion proteins

S. Locarnini, D. Anderson, F. Li, 1994, Journal of clinical microbiology.

Safety, Tolerability, and Pharmacokinetics of ARC‐520 Injection, an RNA Interference‐Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers

D. Lewis, R. Gish, T. Schluep, 2016, Clinical pharmacology in drug development.

Asian Pacific Association for Study of the Liver (APASL)

M. Alter, M. Hashizume, M. Manns, 2003 .

Reply: ‘More viral mutants, less HBsAg clearance? One size may not fit all'

P. Revill, S. Locarnini, A. Thompson, 2016, Gut.

Purification of hepatitis A virus from human feces.

S. Locarnini, I. Gust, A. Coulepis, 1978, Intervirology.

Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment

M. Yuen, D. Wong, R. Gish, 2021, Gut.

RNA interference therapy with ARC-520 Injection results in long term off-therapy antigen reductions in treatment naïve, HBeAg positive and negative patients with chronic HBV

M. Yuen, R. Gish, J. Lau, 2018 .

Dose response and safety of the daily, oral RIG-I agonist Inarigivir (SB 9200) in treatment naïve patients with chronic hepatitis B: results from the 25mg and 50mg cohorts in the ACHIEVE trial

M. Yuen, D. J. Kim, C. Coffin, 2018 .

Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen supression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment

M. Biermer, Wei Cheng, R. Gish, 2020, Journal of Hepatology.

Infection control practices.

S. Locarnini, J. Druce, C. Birch, 1995, The Medical journal of Australia.

Reply:

S. Locarnini, Hai‐ying Zhang, George K.K. Lau, 2004 .

Interpretation and application of virological testing including resistance in chronic hepatitis B.

S. Locarnini, 2005, The Medical journal of Malaysia.

Molecular epidemiology of hepatitis delta virus in the Western Pacific region.

Q. Ning, S. Locarnini, S. Bowden, 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Prevalence of hepatitis G virus antibodies in Queensland blood donors

S. Locarnini, D. S. Bowden, I. Young, 1997, The Medical journal of Australia.

A summary of the 20th International Symposium on Hepatitis C Virus and Related Viruses.

G. Ahlenstiel, J. George, S. Locarnini, 2014, Gastroenterology.

Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro

P. Angus, S. Locarnini, T. Shaw, 1995, Hepatology.

Only the non-glycosylated fraction of hepatitis E virus capsid (open reading frame 2) protein is stable in mammalian cells.

S. Locarnini, J. Torresi, Fan Li, 1999, The Journal of general virology.

A phase 2, open‐label, randomized, multiple‐dose study evaluating Inarigivir in treatment‐naïve patients with chronic hepatitis B

Chun-Jen Liu, M. Yuen, D. J. Kim, 2022, Liver international : official journal of the International Association for the Study of the Liver.

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

C. Gibbs, P. Marcellin, F. Zoulim, 2004, Gastroenterology.

Present and future therapies of hepatitis B: From discovery to cure

B. McMahon, A. Lok, F. Zoulim, 2015, Hepatology.

Differential Reductions in Viral Antigens Expressed from CCCDNAVS Integrated DNA in Treatment Naïve HBEAG Positive and Negative Patients with Chronic HBV after RNA Interference Therapy with ARC-520

M. Yuen, R. Gish, J. Lau, 2016 .

Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs.

A. Lok, Ding‐Shinn Chen, A. Hatzakis, 2015, Journal of hepatology.

Hepatitis C virus infection in Victorian injecting drug users in 1971

S. Locarnini, N. Crofts, L. Moaven, 1993, The Medical journal of Australia.

Antiviral resistance and direct-acting antiviral agents for HCV.

S. Locarnini, A. Aloia, M. Beard, 2012, Antiviral therapy.

Hepatitis B virus mutations associated with antiviral therapy

S. Locarnini, A. Bartholomeusz, S. Locarnini, 2006, Journal of medical virology.

The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound

N. Warner, S. Locarnini, 2008, Hepatology.